6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
below	IN	below	below	below	N	O
and	CC	and	and	and	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Distant	JJ	distant	distant	distant	N	B-AdverseReaction
Spread	NNP	spread	spread	spread	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
Toxin	NNP	toxin	toxin	toxin	N	I-AdverseReaction
Effect	NNP	effect	effect	effect	N	I-AdverseReaction
[	NNP	[	[	[	N	O
seeBoxed	VBD	seeboxed	seeboxed	seebox	N	O
Warning	NNP	warning	warning	warn	N	O
]	NN	]	]	]	N	O

Lack	NN	lack	lack	lack	N	O
of	IN	of	of	of	N	O
Interchangeability	NNP	interchangeability	interchangeability	interchang	N	O
between	IN	between	between	between	N	O
Botulinum	NNP	botulinum	botulinum	botulinum	N	O
Toxin	NNP	toxin	toxin	toxin	N	O
Products	NNP	products	product	product	N	O
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Spread	NN	spread	spread	spread	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
Effects	NNS	effects	effect	effect	N	I-AdverseReaction
from	IN	from	from	from	N	I-AdverseReaction
Toxin	NNP	toxin	toxin	toxin	N	I-AdverseReaction
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Breathing	NNP	breathing	breathing	breath	N	B-AdverseReaction
Difficulties	NNP	difficulties	difficulty	difficulti	N	I-AdverseReaction
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Facial	JJ	facial	facial	facial	N	O
Anatomy	NNP	anatomy	anatomy	anatomi	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Glabellar	NNP	glabellar	glabellar	glabellar	N	O
Lines	NNP	lines	line	line	N	O
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Pre	NNP	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
Neuromuscular	JJ	neuromuscular	neuromuscular	neuromuscular	N	O
Disorders	NNS	disorders	disorder	disord	N	O
[	VBP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Human	NNP	human	human	human	N	O
Albumin	NNP	albumin	albumin	albumin	Y	O
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

Intradermal	NNP	intradermal	intradermal	intraderm	N	B-AdverseReaction
Immune	NNP	immune	immune	immun	N	I-AdverseReaction
Reaction	NNP	reaction	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

7	CD	7	7	7	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Cervical	JJ	cervical	cervical	cervic	N	O
Dystonia	NNP	dystonia	dystonia	dystonia	Y	O

Most	JJS	most	most	most	N	O

commonly	RB	commonly	commonly	commonli	N	O
observed	JJ	observed	observed	observ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
neck	NN	neck	neck	neck	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
eye	NN	eye	eye	eye	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

Glabellar	JJ	glabellar	glabellar	glabellar	N	O
Lines	NNS	lines	line	line	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

Upper	NNP	upper	upper	upper	N	O
Limb	NNP	limb	limb	limb	N	O
Spasticity	NNP	spasticity	spasticity	spastic	Y	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
fall	NN	fall	fall	fall	Y	B-AdverseReaction
and	CC	and	and	and	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Ipsen	NNP	ipsen	ipsen	ipsen	N	O
Biopharmaceuticals	NNP	biopharmaceuticals	biopharmaceuticals	biopharmaceut	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
397	CD	397	397	397	N	O
-	:	-	-	-	N	O
7671	CD	7671	7671	7671	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Cervical	JJ	cervical	cervical	cervic	N	O
Dystonia	NNP	dystonia	dystonia	dystonia	Y	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
357	CD	357	357	357	N	O
cervical	JJ	cervical	cervical	cervic	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
6	CD	6	6	6	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
,	,	,	,	,	N	O
two	CD	two	two	two	N	O
studies	NNS	studies	study	studi	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
single	JJ	single	single	singl	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
placebo	NN	placebo	placebo	placebo	N	O
controlled	VBD	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
optional	JJ	optional	optional	option	N	O
open	JJ	open	open	open	N	O
label	NN	label	label	label	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
dose	JJ	dose	dose	dose	N	O
optimization	NN	optimization	optimization	optim	N	O
(	(	(	(	(	N	O
250	CD	250	250	250	N	O
to	TO	to	to	to	N	O
1000	CD	1000	1000	1000	N	O
Units	NNS	units	unit	unit	N	O
per	IN	per	per	per	N	O
treatment	NN	treatment	treatment	treatment	N	O
)	)	)	)	)	N	O
over	IN	over	over	over	N	O
the	DT	the	the	the	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycles	NNS	cycles	cycle	cycl	N	O
was	VBD	was	wa	wa	N	O
allowed	VBN	allowed	allowed	allow	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
almost	RB	almost	almost	almost	N	O
entirely	RB	entirely	entirely	entir	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
(	(	(	(	(	N	O
99%	CD	99%	99%	99%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
51	CD	51	51	51	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
18	CD	18	18	18	N	O
-	:	-	-	-	N	O
82	CD	82	82	82	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
87%	CD	87%	87%	87%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
;	:	;	;	;	N	O
58.4%	CD	58.4%	58.4%	58.4%	N	O
were	VBD	were	were	were	N	O
women	NNS	women	woman	women	N	O
.	.	.	.	.	N	O

Common	JJ	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
500	CD	500	500	500	N	O
Units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
cervical	JJ	cervical	cervical	cervic	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
neck	NN	neck	neck	neck	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
eye	NN	eye	eye	eye	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
consisting	VBG	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
blurred	JJ	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
reduced	VBD	reduced	reduced	reduc	N	B-AdverseReaction
visual	JJ	visual	visual	visual	N	I-AdverseReaction
acuity	NN	acuity	acuity	acuiti	N	I-AdverseReaction
and	CC	and	and	and	N	O
accommodation	NN	accommodation	accommodation	accommod	N	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
most	JJS	most	most	most	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
became	VBD	became	became	becam	N	O
noticeable	JJ	noticeable	noticeable	notic	N	O
about	IN	about	about	about	N	O
one	CD	one	one	one	N	O
week	NN	week	week	week	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
lasted	VBD	lasted	lasted	last	N	O
several	JJ	several	several	sever	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
higher	JJR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
combined	VBN	combined	combined	combin	N	O
controlled	NNS	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
experience	NN	experience	experience	experi	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
two	CD	two	two	two	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
experienced	VBD	experienced	experienced	experienc	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
withdrawal	VB	withdrawal	withdrawal	withdraw	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
attention	NN	attention	attention	attent	N	I-AdverseReaction
,	,	,	,	,	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
abnormal	JJ	abnormal	abnormal	abnorm	N	I-AdverseReaction
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
compares	VBZ	compares	compare	compar	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycle	NN	cycle	cycle	cycl	N	O
of	IN	of	of	of	N	O
500	CD	500	500	500	N	O
Units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
[	NNP	[	[	[	N	O
seeClinical	JJ	seeclinical	seeclinical	seeclin	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
Common	JJ	common	common	common	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Greater	NNP	greater	greater	greater	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Pooled	NNP	pooled	pooled	pool	N	O
,	,	,	,	,	N	O
Double	NNP	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
Phase	NNP	phase	phase	phase	N	O
of	IN	of	of	of	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNP	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Cervical	NNP	cervical	cervical	cervic	N	O
Dystonia	NNP	dystonia	dystonia	dystonia	Y	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
500	CD	500	500	500	N	O
Units	NNS	units	unit	unit	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
173	CD	173	173	173	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
182	CD	182	182	182	N	O
)	)	)	)	)	N	O

Any	DT	any	any	ani	N	O

Adverse	NN	adverse	adverse	advers	N	O

Reaction	NN	reaction	reaction	reaction	N	O
61	CD	61	61	61	N	O
51	CD	51	51	51	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
30	CD	30	30	30	N	O
23	CD	23	23	23	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
13	CD	13	13	13	N	O
8	CD	8	8	8	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
12	CD	12	12	12	N	O
10	CD	10	10	10	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
5	CD	5	5	5	N	O
4	CD	4	4	4	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
30	CD	30	30	30	N	O
18	CD	18	18	18	N	O

Muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
16	CD	16	16	16	N	O
4	CD	4	4	4	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
7	CD	7	7	7	N	O
3	CD	3	3	3	N	O

Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
28	CD	28	28	28	N	O
15	CD	15	15	15	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
15	CD	15	15	15	N	O
4	CD	4	4	4	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
mouth	VBD	mouth	mouth	mouth	N	I-AdverseReaction
13	CD	13	13	13	N	O
7	CD	7	7	7	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
16	CD	16	16	16	N	O
13	CD	13	13	13	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
11	CD	11	11	11	N	O
9	CD	9	9	9	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
13	CD	13	13	13	N	O
9	CD	9	9	9	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
12	CD	12	12	12	N	O
8	CD	8	8	8	N	O

Dysphonia	NNP	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
6	CD	6	6	6	N	O
2	CD	2	2	2	N	O

Eye	NNP	eye	eye	eye	N	O
Disorders	NNP	disorders	disorder	disord	N	O
7	CD	7	7	7	N	O
2	CD	2	2	2	N	O

Dose	NNP	dose	dose	dose	N	O
-	:	-	-	-	N	O
response	NN	response	response	respons	N	O
relationships	NNS	relationships	relationship	relationship	N	O
for	IN	for	for	for	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
multiple	NN	multiple	multiple	multipl	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
the	DT	the	the	the	N	O
total	NN	total	total	total	N	O
dose	NN	dose	dose	dose	N	O
was	VBD	was	wa	wa	N	O
divided	VBN	divided	divided	divid	N	O
between	IN	between	between	between	N	O
two	CD	two	two	two	N	O
muscles	NNS	muscles	muscle	muscl	N	O
(	(	(	(	(	N	O
the	DT	the	the	the	N	O
sternocleidomastoid	NN	sternocleidomastoid	sternocleidomastoid	sternocleidomastoid	N	O
and	CC	and	and	and	N	O
splenius	VB	splenius	splenius	spleniu	N	O
capitis	NN	capitis	capitis	capiti	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Common	JJ	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
by	IN	by	by	by	N	O
Dose	NNP	dose	dose	dose	N	O
in	IN	in	in	in	N	O
Fixed	NNP	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
Study	NNP	study	study	studi	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Cervical	NNP	cervical	cervical	cervic	N	O
Dystonia	NNP	dystonia	dystonia	dystonia	Y	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
Dose	NN	dose	dose	dose	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
250	CD	250	250	250	N	O
Units	NNS	units	unit	unit	N	O
500	CD	500	500	500	N	O
Units	NNS	units	unit	unit	N	O
1000	CD	1000	1000	1000	N	O
Units	NNS	units	unit	unit	N	O

Any	DT	any	any	ani	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Event	NNP	event	event	event	N	O
30%	CD	30%	30%	30%	N	O
37%	CD	37%	37%	37%	N	O
65%	CD	65%	65%	65%	N	O
83%	CD	83%	83%	83%	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
5%	CD	5%	5%	5%	N	O
21%	CD	21%	21%	21%	N	O
29%	CD	29%	29%	29%	N	O
39%	CD	39%	39%	39%	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
Mouth	NNP	mouth	mouth	mouth	N	I-AdverseReaction
10%	CD	10%	10%	10%	N	O
21%	CD	21%	21%	21%	N	O
18%	CD	18%	18%	18%	N	O
39%	CD	39%	39%	39%	N	O

Muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
Weakness	NNP	weakness	weakness	weak	Y	I-AdverseReaction
0%	CD	0%	0%	0%	N	O
11%	CD	11%	11%	11%	N	O
12%	CD	12%	12%	12%	N	O
56%	CD	56%	56%	56%	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
Site	NNP	site	site	site	N	I-AdverseReaction
Discomfort	NNP	discomfort	discomfort	discomfort	Y	I-AdverseReaction
10%	CD	10%	10%	10%	N	O
5%	CD	5%	5%	5%	N	O
18%	CD	18%	18%	18%	N	O
22%	CD	22%	22%	22%	N	O

Dysphonia	NNP	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O
18%	CD	18%	18%	18%	N	O
28%	CD	28%	28%	28%	N	O

Facial	JJ	facial	facial	facial	N	B-AdverseReaction
Paresis	NNP	paresis	paresis	paresi	Y	I-AdverseReaction
0%	CD	0%	0%	0%	N	O
5%	CD	5%	5%	5%	N	O
0%	CD	0%	0%	0%	N	O
11%	CD	11%	11%	11%	N	O

Eye	NNP	eye	eye	eye	N	O
Disorders	NNP	disorders	disorder	disord	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O
6%	CD	6%	6%	6%	N	O
17%	CD	17%	17%	17%	N	O

Injection	NNP	injection	injection	inject	Y	O
Site	NNP	site	site	site	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

Injection	NN	injection	injection	inject	Y	B-AdverseReaction

site	NN	site	site	site	N	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
following	VBG	following	following	follow	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
administration	NN	administration	administration	administr	N	O
.	.	.	.	.	N	O

Less	NNP	less	le	less	N	O
Common	NNP	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
less	RBR	less	le	less	N	O
frequently	RB	frequently	frequently	frequent	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Breathing	NNP	breathing	breathing	breath	N	O
Difficulty	NN	difficulty	difficulty	difficulti	N	O

Breathing	VBG	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
approximately	RB	approximately	approximately	approxim	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
following	VBG	following	following	follow	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
administration	NN	administration	administration	administr	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
phase	NN	phase	phase	phase	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
consisted	VBD	consisted	consisted	consist	N	O
mainly	RB	mainly	mainly	mainli	N	O
of	IN	of	of	of	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
from	IN	from	from	from	N	O
last	JJ	last	last	last	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
approximately	RB	approximately	approximately	approxim	N	O
one	CD	one	one	one	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
was	VBD	was	wa	wa	N	O
approximately	RB	approximately	approximately	approxim	N	O
three	CD	three	three	three	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
incidences	NNS	incidences	incidence	incid	N	O
of	IN	of	of	of	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
5%	CD	5%	5%	5%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
500	CD	500	500	500	N	O
Units	NNS	units	unit	unit	N	O
group	NN	group	group	group	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
included	VBD	included	included	includ	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
in	IN	in	in	in	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
atrophy	NN	atrophy	atrophy	atrophi	Y	I-AdverseReaction
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Findings	NNS	findings	finding	find	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
exhibited	VBD	exhibited	exhibited	exhibit	N	O
a	DT	a	a	a	N	O
small	JJ	small	small	small	N	B-Severity
increase	NN	increase	increase	increas	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
0.23	CD	0.23	0.23	0.23	N	O
mol	RB	mol	mol	mol	N	O
L	NNP	l	l	l	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	I-AdverseReaction
mean	JJ	mean	mean	mean	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
glucose	RB	glucose	glucose	glucos	Y	I-AdverseReaction
relative	JJ	relative	relative	rel	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
program	NN	program	program	program	N	O
but	CC	but	but	but	N	O
could	MD	could	could	could	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
factor	NN	factor	factor	factor	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
is	VBZ	is	is	is	N	O
difficult	JJ	difficult	difficult	difficult	N	O
to	TO	to	to	to	N	O
control	VB	control	control	control	N	O
.	.	.	.	.	N	O

Electrocardiographic	JJ	electrocardiographic	electrocardiographic	electrocardiograph	N	O
Findings	NNS	findings	finding	find	N	O

ECG	NN	ecg	ecg	ecg	Y	O
measurements	NNS	measurements	measurement	measur	N	O
were	VBD	were	were	were	N	O
only	RB	only	only	onli	N	O
recorded	VBN	recorded	recorded	record	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
limited	JJ	limited	limited	limit	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
study	NN	study	study	studi	N	O
without	IN	without	without	without	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
or	CC	or	or	or	N	O
active	JJ	active	active	activ	N	O
control	NN	control	control	control	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
study	NN	study	study	studi	N	O
showed	VBD	showed	showed	show	N	O
a	DT	a	a	a	N	O
statistically	RB	statistically	statistically	statist	N	O
significant	JJ	significant	significant	signific	N	O
reduction	NN	reduction	reduction	reduct	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
baseline	VB	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
averaging	VBG	averaging	averaging	averag	N	O
about	IN	about	about	about	N	O
three	CD	three	three	three	N	O
beats	NNS	beats	beat	beat	N	O
per	IN	per	per	per	N	O
minute	NN	minute	minute	minut	N	O
,	,	,	,	,	N	O
observed	VBD	observed	observed	observ	N	O
thirty	NN	thirty	thirty	thirti	N	O
minutes	NNS	minutes	minute	minut	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

Glabellar	JJ	glabellar	glabellar	glabellar	N	O
Lines	NNS	lines	line	line	N	O

In	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
following	VBG	following	following	follow	N	O
injection	NN	injection	injection	inject	Y	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
reflects	VBZ	reflects	reflects	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
398	CD	398	398	398	N	O
patients	NNS	patients	patient	patient	N	O
19	CD	19	19	19	N	O
to	TO	to	to	to	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	NN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
that	WDT	that	that	that	N	O
assessed	VBD	assessed	assessed	assess	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
temporary	JJ	temporary	temporary	temporari	N	O
improvement	NN	improvement	improvement	improv	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
appearance	NN	appearance	appearance	appear	N	O
of	IN	of	of	of	N	O
glabellar	JJ	glabellar	glabellar	glabellar	N	O
lines	NNS	lines	line	line	N	O
[	RB	[	[	[	N	O
seeClinical	JJ	seeclinical	seeclinical	seeclin	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
cause	NN	cause	cause	caus	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
48%	CD	48%	48%	48%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
33%	CD	33%	33%	33%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
Common	JJ	common	common	common	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
1%	CD	1%	1%	1%	N	O
Incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
Pooled	NNP	pooled	pooled	pool	N	O
,	,	,	,	,	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
for	IN	for	for	for	N	O
Glabellar	NNP	glabellar	glabellar	glabellar	N	O
Lines	NNS	lines	line	line	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
by	IN	by	by	by	N	O
Body	NNP	body	body	bodi	N	O
System	NNP	system	system	system	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
n	VBZ	n	n	n	N	O
398	CD	398	398	398	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Placebon	VBZ	placebon	placebon	placebon	N	O
496	CD	496	496	496	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Any	DT	any	any	ani	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
48	CD	48	48	48	N	O
33	CD	33	33	33	N	O

Eye	NN	eye	eye	eye	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Eyelid	NNP	eyelid	eyelid	eyelid	N	B-AdverseReaction
Edema	NNP	edema	edema	edema	Y	I-AdverseReaction
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
Ptosis	NNP	ptosis	ptosis	ptosi	Y	I-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
Site	NNP	site	site	site	N	I-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
Site	NNP	site	site	site	N	I-AdverseReaction
Reaction	NNP	reaction	reaction	reaction	N	I-AdverseReaction
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
10	CD	10	10	10	N	O
4	CD	4	4	4	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infection	NNP	infection	infection	infect	Y	I-AdverseReaction
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Blood	NNP	blood	blood	blood	N	B-AdverseReaction
Present	NNP	present	present	present	N	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Urine	NNP	urine	urine	urin	N	I-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
9	CD	9	9	9	N	O
5	CD	5	5	5	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
safety	NN	safety	safety	safeti	N	O
database	NN	database	database	databas	N	O
,	,	,	,	,	N	O
where	WRB	where	where	where	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
twelve	VB	twelve	twelve	twelv	N	O
treatments	NNS	treatments	treatment	treatment	N	O
with	IN	with	with	with	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
57%	CD	57%	57%	57%	N	O
(	(	(	(	(	N	O
1425	CD	1425	1425	1425	N	O
2491	CD	2491	2491	2491	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBN	reported	reported	report	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
URI	NNP	uri	uri	uri	N	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
bruising	NN	bruising	bruising	bruis	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
numbness	JJ	numbness	numbness	numb	Y	I-AdverseReaction
,	,	,	,	,	N	O
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	I-AdverseReaction
,	,	,	,	,	N	O
tenderness	NN	tenderness	tenderness	tender	Y	I-AdverseReaction
,	,	,	,	,	N	O
tingling	VBG	tingling	tingling	tingl	Y	I-AdverseReaction
,	,	,	,	,	N	O
itching	VBG	itching	itching	itch	Y	I-AdverseReaction
,	,	,	,	,	N	O
stinging	VBG	stinging	stinging	sting	Y	I-AdverseReaction
,	,	,	,	,	N	O
warmth	NN	warmth	warmth	warmth	N	I-AdverseReaction
,	,	,	,	,	N	O
irritation	NN	irritation	irritation	irrit	N	I-AdverseReaction
,	,	,	,	,	N	O
tightness	NN	tightness	tightness	tight	N	I-AdverseReaction
,	,	,	,	,	N	O
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	NN	adverse	adverse	advers	N	O

reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
after	IN	after	after	after	N	O
repeated	VBN	repeated	repeated	repeat	N	O
injections	NNS	injections	injection	inject	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
included	VBD	included	included	includ	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
pharyngolaryngeal	NN	pharyngolaryngeal	pharyngolaryngeal	pharyngolaryng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	B-AdverseReaction
dermatitis	NN	dermatitis	dermatitis	dermat	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
increase	VB	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
safety	NN	safety	safety	safeti	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
multiple	JJ	multiple	multiple	multipl	N	O
re	NN	re	re	re	N	O
-	:	-	-	-	N	O
treatments	NNS	treatments	treatment	treatment	N	O
at	IN	at	at	at	N	O
intervals	NNS	intervals	interval	interv	N	O
three	CD	three	three	three	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
mild	JJ	mild	mild	mild	N	B-Severity
to	TO	to	to	to	N	O
moderate	VB	moderate	moderate	moder	N	B-Severity
in	IN	in	in	in	N	O
severity	NN	severity	severity	sever	N	O
and	CC	and	and	and	N	O
resolved	VBN	resolved	resolved	resolv	N	O
over	IN	over	over	over	N	O
several	JJ	several	several	sever	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

[	JJ	[	[	[	N	O
seeDosage	NN	seedosage	seedosage	seedosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Upper	NNP	upper	upper	upper	N	O
Limb	NNP	limb	limb	limb	N	O
Spasticity	NNP	spasticity	spasticity	spastic	Y	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
lists	VBZ	lists	list	list	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
dose	NN	dose	dose	dose	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
more	JJR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
double	JJ	double	double	doubl	N	O
blind	NN	blind	blind	blind	Y	O
studies	NNS	studies	study	studi	N	O
evaluating	VBG	evaluating	evaluating	evalu	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
upper	JJ	upper	upper	upper	N	O
limb	NN	limb	limb	limb	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
with	IN	with	with	with	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
Common	JJ	common	common	common	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Observed	NNP	observed	observed	observ	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
in	IN	in	in	in	N	O
Pooled	NNP	pooled	pooled	pool	N	O
,	,	,	,	,	N	O
Double	NNP	double	double	doubl	N	O
-	:	-	-	-	N	O
Blind	NNP	blind	blind	blind	Y	O
Trials	NNP	trials	trial	trial	N	O
of	IN	of	of	of	N	O
Patients	NNPS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Upper	NNP	upper	upper	upper	N	O
Limb	NNP	limb	limb	limb	N	O
Spasticity	NNP	spasticity	spasticity	spastic	Y	O
Reported	VBD	reported	reported	report	N	O
More	RBR	more	more	more	N	O
Frequently	RB	frequently	frequently	frequent	N	O
than	IN	than	than	than	N	O
with	IN	with	with	with	N	O
Placebo	NNP	placebo	placebo	placebo	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
Placebo	NN	placebo	placebo	placebo	N	O

500	CD	500	500	500	N	O
Units	NNS	units	unit	unit	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
197	CD	197	197	197	N	O
)	)	)	)	)	N	O
1000	CD	1000	1000	1000	N	O
Units	NNP	units	unit	unit	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
194	CD	194	194	194	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
279	CD	279	279	279	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O

and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
4	CD	4	4	4	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

Influenza	NNP	influenza	influenza	influenza	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Infection	NN	infection	infection	infect	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O
1	CD	1	1	1	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Convulsion	NN	convulsion	convulsion	convuls	Y	B-AdverseReaction
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Syncope	NNP	syncope	syncope	syncop	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Hypoaesthesia	$	hypoaesthesia	hypoaesthesia	hypoaesthesia	Y	B-AdverseReaction
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Partial	JJ	partial	partial	partial	N	B-AdverseReaction
seizures	VBZ	seizures	seizure	seizur	Y	I-AdverseReaction
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
poisoning	NN	poisoning	poisoning	poison	Y	O
and	CC	and	and	and	N	O
procedural	JJ	procedural	procedural	procedur	N	O
complications	NNS	complications	complication	complic	N	O

Fall	NN	fall	fall	fall	Y	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Injury	NNP	injury	injury	injuri	Y	B-AdverseReaction
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Investigation	NN	investigation	investigation	investig	Y	O

Blood	NNP	blood	blood	blood	N	B-AdverseReaction
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Depression	NNP	depression	depression	depress	Y	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O

Injection	NNP	injection	injection	inject	Y	O
Site	NNP	site	site	site	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

Injection	NN	injection	injection	inject	Y	B-AdverseReaction

site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
bruising	NN	bruising	bruising	bruis	Y	I-AdverseReaction
,	,	,	,	,	N	O
haemorrhage	NN	haemorrhage	haemorrhage	haemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
erythema	NN	erythema	erythema	erythema	Y	I-AdverseReaction
haematoma	NN	haematoma	haematoma	haematoma	Y	I-AdverseReaction
etc	FW	etc	etc	etc	N	O
.	.	.	.	.	N	O
)	)	)	)	)	N	O

have	VB	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
following	VBG	following	following	follow	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Less	NNP	less	le	less	N	O
Common	NNP	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
pooled	JJ	pooled	pooled	pool	N	O
analysis	NN	analysis	analysis	analysi	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
2%	CD	2%	2%	2%	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
included	VBD	included	included	includ	N	O
dysphagia	JJ	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
0.5%	CD	0.5%	0.5%	0.5%	N	O
,	,	,	,	,	N	O
gait	NN	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
0.5%	CD	0.5%	0.5%	0.5%	N	O
,	,	,	,	,	N	O
hypertonia	NN	hypertonia	hypertonia	hypertonia	Y	B-AdverseReaction
0.5%	CD	0.5%	0.5%	0.5%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sensation	NN	sensation	sensation	sensat	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
heaviness	NN	heaviness	heaviness	heavi	N	I-AdverseReaction
0.3%	CD	0.3%	0.3%	0.3%	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
,	,	,	,	,	N	O
photophobia	NN	photophobia	photophobia	photophobia	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	JJ	influenza	influenza	influenza	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
illness	NN	illness	illness	ill	N	I-AdverseReaction
,	,	,	,	,	N	O
amyotrophy	NN	amyotrophy	amyotrophy	amyotrophi	Y	B-AdverseReaction
,	,	,	,	,	N	O
burning	VBG	burning	burning	burn	N	B-AdverseReaction
sensation	NN	sensation	sensation	sensat	N	I-AdverseReaction
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
paresis	NN	paresis	paresis	paresi	Y	I-AdverseReaction
,	,	,	,	,	N	O
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
excessive	JJ	excessive	excessive	excess	N	B-AdverseReaction
granulation	NN	granulation	granulation	granul	N	I-AdverseReaction
tissue	NN	tissue	tissue	tissu	N	I-AdverseReaction
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
proteins	NNS	proteins	protein	protein	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
potential	JJ	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
across	IN	across	across	across	N	O
products	NNS	products	product	product	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
class	NN	class	class	class	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O

Cervical	JJ	cervical	cervical	cervic	N	O
Dystonia	NNP	dystonia	dystonia	dystonia	Y	O

About	IN	about	about	about	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
developed	VBN	developed	developed	develop	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
(	(	(	(	(	N	O
binding	VBG	binding	binding	bind	N	O
or	CC	or	or	or	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
)	)	)	)	)	N	O
over	IN	over	over	over	N	O
time	NN	time	time	time	N	O
with	IN	with	with	with	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Glabellar	JJ	glabellar	glabellar	glabellar	N	O
Lines	NNS	lines	line	line	N	O

Testing	VBG	testing	testing	test	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
performed	VBN	performed	performed	perform	N	O
for	IN	for	for	for	N	O
1554	CD	1554	1554	1554	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
up	RP	up	up	up	N	O
to	TO	to	to	to	N	O
nine	CD	nine	nine	nine	N	O
cycles	NNS	cycles	cycle	cycl	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
0.13%	CD	0.13%	0.13%	0.13%	N	O
)	)	)	)	)	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
binding	VBG	binding	binding	bind	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
additional	JJ	additional	additional	addit	N	O
subjects	NNS	subjects	subject	subject	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
binding	VBG	binding	binding	bind	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
after	IN	after	after	after	N	O
receiving	VBG	receiving	receiving	receiv	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

None	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
subjects	NNS	subjects	subject	subject	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

Upper	NNP	upper	upper	upper	N	O
Limb	NNP	limb	limb	limb	N	O
Spasticity	NNP	spasticity	spasticity	spastic	Y	O

From	IN	from	from	from	N	O
230	CD	230	230	230	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
binding	VBG	binding	binding	bind	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
positive	JJ	positive	positive	posit	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
17	CD	17	17	17	N	O
developed	JJ	developed	developed	develop	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
those	DT	those	those	those	N	O
17	CD	17	17	17	N	O
subjects	NNS	subjects	subject	subject	N	O
,	,	,	,	,	N	O
10	CD	10	10	10	N	O
subjects	NNS	subjects	subject	subject	N	O
developed	VBD	developed	developed	develop	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
additional	JJ	additional	additional	addit	N	O
51	CD	51	51	51	N	O
subjects	NNS	subjects	subject	subject	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
separate	JJ	separate	separate	separ	N	O
repeat	NN	repeat	repeat	repeat	N	O
dose	NN	dose	dose	dose	N	O
study	NN	study	study	studi	N	O
were	VBD	were	were	were	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
only	RB	only	only	onli	N	O
.	.	.	.	.	N	O

None	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
subjects	NNS	subjects	subject	subject	N	O
tested	VBN	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
total	JJ	total	total	total	N	O
,	,	,	,	,	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
281	CD	281	281	281	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
studies	NNS	studies	study	studi	N	O
and	CC	and	and	and	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
,	,	,	,	,	N	O
3.6%	CD	3.6%	3.6%	3.6%	N	O
developed	VBD	developed	developed	develop	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
binding	NN	binding	binding	bind	N	O
and	CC	and	and	and	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
continue	VBP	continue	continue	continu	N	O
to	TO	to	to	to	N	O
experience	VB	experience	experience	experi	N	O
clinical	JJ	clinical	clinical	clinic	N	O
benefit	NN	benefit	benefit	benefit	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
DISTANT	NNP	distant	distant	distant	N	B-AdverseReaction
SPREAD	NNP	spread	spread	spread	N	I-AdverseReaction
OF	NNP	of	of	of	N	I-AdverseReaction
TOXIN	NNP	toxin	toxin	toxin	N	I-AdverseReaction
EFFECT	NNP	effect	effect	effect	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
DISTANT	NNP	distant	distant	distant	N	B-AdverseReaction
SPREAD	NNP	spread	spread	spread	N	I-AdverseReaction
OF	NNP	of	of	of	N	I-AdverseReaction
TOXIN	NNP	toxin	toxin	toxin	N	I-AdverseReaction
EFFECT	NNP	effect	effect	effect	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Postmarketing	NNP	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
indicate	VBP	indicate	indicate	indic	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	B-Factor
spread	VB	spread	spread	spread	N	B-AdverseReaction
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
area	NN	area	area	area	N	O
of	IN	of	of	of	N	O
injection	NN	injection	injection	inject	Y	O
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	I-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
may	MD	may	may	may	N	B-Factor
include	VB	include	include	includ	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
generalized	VBN	generalized	generalized	gener	N	B-AdverseReaction
muscle	NN	muscle	muscle	muscl	N	I-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
ptosis	NN	ptosis	ptosis	ptosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysarthria	NN	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
incontinence	NN	incontinence	incontinence	incontin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
breathing	NN	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
hours	NNS	hours	hour	hour	N	O
to	TO	to	to	to	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

Swallowing	VBG	swallowing	swallowing	swallow	N	B-AdverseReaction
and	CC	and	and	and	N	O
breathing	VBG	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
life	NN	life	life	life	N	O
threatening	VBG	threatening	threatening	threaten	N	O
and	CC	and	and	and	N	O
there	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
is	VBZ	is	is	is	N	O
probably	RB	probably	probably	probabl	N	O
greatest	JJS	greatest	greatest	greatest	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
but	CC	but	but	but	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
can	MD	can	can	can	N	O
also	RB	also	also	also	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
underlying	JJ	underlying	underlying	underli	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
would	MD	would	would	would	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
unapproved	JJ	unapproved	unapproved	unapprov	N	O
uses	NNS	uses	us	use	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
approved	JJ	approved	approved	approv	N	O
indications	NNS	indications	indication	indic	N	O
,	,	,	,	,	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
spread	NN	spread	spread	spread	N	O
of	IN	of	of	of	N	O
effect	NN	effect	effect	effect	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
comparable	JJ	comparable	comparable	compar	N	O
to	TO	to	to	to	N	O
or	CC	or	or	or	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
maximum	NN	maximum	maximum	maximum	N	O
recommended	VBD	recommended	recommended	recommend	N	O
total	JJ	total	total	total	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
\n\n\n\n	JJ	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
DISTANT	NNP	distant	distant	distant	N	B-AdverseReaction
SPREAD	NNP	spread	spread	spread	N	I-AdverseReaction
OF	NNP	of	of	of	N	I-AdverseReaction
TOXIN	NNP	toxin	toxin	toxin	N	I-AdverseReaction
EFFECT	NNP	effect	effect	effect	N	I-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
\n\n\n\n	VBD	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
The	DT	the	the	the	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	B-Factor
spread	VB	spread	spread	spread	N	B-AdverseReaction
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
area	NN	area	area	area	N	O
of	IN	of	of	of	N	O
injection	NN	injection	injection	inject	Y	O
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	I-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
hours	NNS	hours	hour	hour	N	O
to	TO	to	to	to	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

Swallowing	VBG	swallowing	swallowing	swallow	N	B-AdverseReaction
and	CC	and	and	and	N	O
breathing	VBG	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
life	NN	life	life	life	N	O
threatening	VBG	threatening	threatening	threaten	N	O
and	CC	and	and	and	N	O
there	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
is	VBZ	is	is	is	N	O
probably	RB	probably	probably	probabl	N	O
greatest	JJS	greatest	greatest	greatest	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
but	CC	but	but	but	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
can	MD	can	can	can	N	O
also	RB	also	also	also	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
underlying	JJ	underlying	underlying	underli	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
would	MD	would	would	would	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O
\n	$	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
potency	NN	potency	potency	potenc	N	O
Units	NNP	units	unit	unit	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
interchangeable	JJ	interchangeable	interchangeable	interchang	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
preparations	NNS	preparations	preparation	prepar	N	O
of	IN	of	of	of	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
biological	JJ	biological	biological	biolog	N	O
activity	NN	activity	activity	activ	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
or	CC	or	or	or	N	O
converted	VBN	converted	converted	convert	N	O
into	IN	into	into	into	N	O
units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
administration	NN	administration	administration	administr	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
exceeded	VBN	exceeded	exceeded	exceed	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Immediate	NNP	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
required	VBN	required	required	requir	N	O
in	IN	in	in	in	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	B-AdverseReaction
,	,	,	,	,	N	O
speech	NN	speech	speech	speech	N	B-AdverseReaction
or	CC	or	or	or	N	O
swallowing	VBG	swallowing	swallowing	swallow	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Concomitant	NNP	concomitant	concomitant	concomit	N	O
neuromuscular	JJ	neuromuscular	neuromuscular	neuromuscular	N	O
disorder	NN	disorder	disorder	disord	N	O
may	MD	may	may	may	N	O
exacerbate	VB	exacerbate	exacerbate	exacerb	N	O
clinical	JJ	clinical	clinical	clinic	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
contains	VBZ	contains	contains	contain	N	O
human	JJ	human	human	human	N	O
albumin	NN	albumin	albumin	albumin	Y	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
transmission	NN	transmission	transmission	transmiss	N	O
of	IN	of	of	of	N	O
Creutzfeldt	NNP	creutzfeldt	creutzfeldt	creutzfeldt	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Jakob	NNP	jakob	jakob	jakob	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
CJD	NNP	cjd	cjd	cjd	Y	B-AdverseReaction
)	)	)	)	)	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	B-Negation
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
transmission	NN	transmission	transmission	transmiss	N	I-Negation
of	IN	of	of	of	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
diseases	NNS	diseases	disease	diseas	N	I-AdverseReaction
or	CC	or	or	or	N	O
CJD	NNP	cjd	cjd	cjd	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
ever	RB	ever	ever	ever	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
for	IN	for	for	for	N	O
albumin	NN	albumin	albumin	albumin	Y	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Lack	NN	lack	lack	lack	N	O
of	IN	of	of	of	N	O
Interchangeability	NNP	interchangeability	interchangeability	interchang	N	O
between	IN	between	between	between	N	O
Botulinum	NNP	botulinum	botulinum	botulinum	N	O
Toxin	NNP	toxin	toxin	toxin	N	O
Products	NNS	products	product	product	N	O

The	DT	the	the	the	N	O
potency	NN	potency	potency	potenc	N	O
Units	NNP	units	unit	unit	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
specific	JJ	specific	specific	specif	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
preparation	NN	preparation	preparation	prepar	N	O
and	CC	and	and	and	N	O
assay	VB	assay	assay	assay	N	O
method	NN	method	method	method	N	O
utilized	JJ	utilized	utilized	util	N	O
.	.	.	.	.	N	O

They	PRP	they	they	they	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
interchangeable	JJ	interchangeable	interchangeable	interchang	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
preparations	NNS	preparations	preparation	prepar	N	O
of	IN	of	of	of	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
biological	JJ	biological	biological	biolog	N	O
activity	NN	activity	activity	activ	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
or	CC	or	or	or	N	O
converted	VBN	converted	converted	convert	N	O
into	IN	into	into	into	N	O
units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
assessed	VBN	assessed	assessed	assess	N	O
with	IN	with	with	with	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
specific	JJ	specific	specific	specif	N	O
assay	VBP	assay	assay	assay	N	O
method	JJ	method	method	method	N	O
[	NNP	[	[	[	N	O
seeDescription	NN	seedescription	seedescription	seedescript	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Spread	NNP	spread	spread	spread	N	O
of	IN	of	of	of	N	O
Toxin	NNP	toxin	toxin	toxin	N	O
Effect	NNP	effect	effect	effect	N	O

Post	NNP	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
approved	VBD	approved	approved	approv	N	O
botulinum	JJ	botulinum	botulinum	botulinum	N	O
toxins	NNS	toxins	toxin	toxin	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	B-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
be	VB	be	be	be	N	O
observed	VBN	observed	observed	observ	N	O
beyond	IN	beyond	beyond	beyond	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
local	JJ	local	local	local	N	I-AdverseReaction
injection	NN	injection	injection	inject	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
are	VBP	are	are	are	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
of	IN	of	of	of	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	B-Factor
include	VB	include	include	includ	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
generalized	VBN	generalized	generalized	gener	N	B-AdverseReaction
muscle	NN	muscle	muscle	muscl	N	I-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
ptosis	NN	ptosis	ptosis	ptosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysarthria	NN	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
incontinence	NN	incontinence	incontinence	incontin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
breathing	NN	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
hours	NNS	hours	hour	hour	N	O
to	TO	to	to	to	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

Swallowing	VBG	swallowing	swallowing	swallow	N	B-AdverseReaction
and	CC	and	and	and	N	O
breathing	VBG	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
life	NN	life	life	life	N	O
threatening	VBG	threatening	threatening	threaten	N	O
and	CC	and	and	and	N	O
there	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
spread	NN	spread	spread	spread	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
toxin	NN	toxin	toxin	toxin	N	I-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
is	VBZ	is	is	is	N	O
probably	RB	probably	probably	probabl	N	O
greatest	JJS	greatest	greatest	greatest	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
but	CC	but	but	but	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
can	MD	can	can	can	N	O
also	RB	also	also	also	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
underlying	JJ	underlying	underlying	underli	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
would	MD	would	would	would	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
unapproved	JJ	unapproved	unapproved	unapprov	N	O
uses	NNS	uses	us	use	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
spasticity	NN	spasticity	spasticity	spastic	Y	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
approved	JJ	approved	approved	approv	N	O
indications	NNS	indications	indication	indic	N	O
,	,	,	,	,	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
consistent	VBP	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
spread	NN	spread	spread	spread	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
toxin	NN	toxin	toxin	toxin	N	I-AdverseReaction
effect	NN	effect	effect	effect	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
comparable	JJ	comparable	comparable	compar	N	O
to	TO	to	to	to	N	O
or	CC	or	or	or	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
maximum	NN	maximum	maximum	maximum	N	O
recommended	VBD	recommended	recommended	recommend	N	O
total	JJ	total	total	total	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	O
and	CC	and	and	and	N	O
Breathing	NNP	breathing	breathing	breath	N	O
Difficulties	NNS	difficulties	difficulty	difficulti	N	O

Treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
products	NNS	products	product	product	N	O
can	MD	can	can	can	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
swallowing	NN	swallowing	swallowing	swallow	N	B-AdverseReaction
or	CC	or	or	or	N	O
breathing	NN	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
swallowing	NN	swallowing	swallowing	swallow	N	O
or	CC	or	or	or	N	O
breathing	VBG	breathing	breathing	breath	N	O
difficulties	NNS	difficulties	difficulty	difficulti	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
more	RBR	more	more	more	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
complications	NNS	complications	complication	complic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
most	JJS	most	most	most	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
this	DT	this	this	thi	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
consequence	NN	consequence	consequence	consequ	N	O
of	IN	of	of	of	N	O
weakening	NN	weakening	weakening	weaken	N	O
of	IN	of	of	of	N	O
muscles	NNS	muscles	muscle	muscl	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
area	NN	area	area	area	N	O
of	IN	of	of	of	N	O
injection	NN	injection	injection	inject	Y	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
involved	VBN	involved	involved	involv	N	O
in	IN	in	in	in	N	O
breathing	VBG	breathing	breathing	breath	N	O
or	CC	or	or	or	N	O
swallowing	VBG	swallowing	swallowing	swallow	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
distant	JJ	distant	distant	distant	N	O
effects	NNS	effects	effect	effect	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
additional	JJ	additional	additional	addit	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
muscles	NNS	muscles	muscle	muscl	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
involved	VBN	involved	involved	involv	N	O
[	JJ	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Deaths	NNS	deaths	death	death	N	B-AdverseReaction
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
complication	NN	complication	complication	complic	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	B-Severity
dysphagia	NNS	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
.	.	.	.	.	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
may	MD	may	may	may	N	O
persist	VB	persist	persist	persist	N	O
for	IN	for	for	for	N	O
several	JJ	several	several	sever	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
require	VBP	require	require	requir	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
feeding	NN	feeding	feeding	feed	N	O
tube	NN	tube	tube	tube	N	O
to	TO	to	to	to	N	O
maintain	VB	maintain	maintain	maintain	N	O
adequate	JJ	adequate	adequate	adequ	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
and	CC	and	and	and	N	O
hydration	NN	hydration	hydration	hydrat	N	O
.	.	.	.	.	N	O

Aspiration	NN	aspiration	aspiration	aspir	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
from	IN	from	from	from	N	O
severe	JJ	severe	severe	sever	N	B-Severity
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
particular	JJ	particular	particular	particular	N	O
risk	NN	risk	risk	risk	N	O
when	WRB	when	when	when	N	O
treating	VBG	treating	treating	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
whom	WP	whom	whom	whom	N	O
swallowing	VBG	swallowing	swallowing	swallow	N	O
or	CC	or	or	or	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	O
function	NN	function	function	function	N	O
is	VBZ	is	is	is	N	O
already	RB	already	already	alreadi	N	O
compromised	VBN	compromised	compromised	compromis	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
cervical	JJ	cervical	cervical	cervic	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxins	NNS	toxins	toxin	toxin	N	O
may	MD	may	may	may	N	B-Factor
weaken	VB	weaken	weaken	weaken	N	B-AdverseReaction
neck	NN	neck	neck	neck	N	I-AdverseReaction
muscles	NNS	muscles	muscle	muscl	N	I-AdverseReaction
that	WDT	that	that	that	N	O
serve	VBP	serve	serve	serv	N	O
as	IN	as	a	as	N	O
accessory	JJ	accessory	accessory	accessori	N	O
muscles	NNS	muscles	muscle	muscl	N	O
of	IN	of	of	of	N	O
ventilation	NN	ventilation	ventilation	ventil	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
critical	JJ	critical	critical	critic	N	B-Severity
loss	NN	loss	loss	loss	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
breathing	VBG	breathing	breathing	breath	N	I-AdverseReaction
capacity	NN	capacity	capacity	capac	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	O
disorders	NNS	disorders	disorder	disord	N	O
who	WP	who	who	who	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
become	VBN	become	become	becom	N	O
dependent	JJ	dependent	dependent	depend	N	O
upon	IN	upon	upon	upon	N	O
these	DT	these	these	these	N	O
accessory	JJ	accessory	accessory	accessori	N	O
muscles	NNS	muscles	muscle	muscl	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
post	VBN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
breathing	VBG	breathing	breathing	breath	N	B-AdverseReaction
difficulties	NNS	difficulties	difficulty	difficulti	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	B-Factor
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
should	MD	should	should	should	N	O
they	PRP	they	they	they	N	O
develop	VB	develop	develop	develop	N	O
problems	NNS	problems	problem	problem	N	O
with	IN	with	with	with	N	O
swallowing	NN	swallowing	swallowing	swallow	N	O
,	,	,	,	,	N	O
speech	NN	speech	speech	speech	N	O
or	CC	or	or	or	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
disorders	NNS	disorders	disorder	disord	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
within	IN	within	within	within	N	O
hours	NNS	hours	hour	hour	N	O
to	TO	to	to	to	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
with	IN	with	with	with	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Facial	JJ	facial	facial	facial	N	O
Anatomy	NNP	anatomy	anatomy	anatomi	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Glabellar	NNP	glabellar	glabellar	glabellar	N	O
Lines	NNS	lines	line	line	N	O

Caution	NN	caution	caution	caution	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
exercised	VBN	exercised	exercised	exercis	N	O
when	WRB	when	when	when	N	O
administering	VBG	administering	administering	administ	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
surgical	JJ	surgical	surgical	surgic	N	O
alterations	NNS	alterations	alteration	alter	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
facial	JJ	facial	facial	facial	N	O
anatomy	NN	anatomy	anatomy	anatomi	N	O
,	,	,	,	,	N	O
excessive	JJ	excessive	excessive	excess	N	O
weakness	NN	weakness	weakness	weak	Y	O
or	CC	or	or	or	N	O
atrophy	NN	atrophy	atrophy	atrophi	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
target	NN	target	target	target	N	O
muscle	NN	muscle	muscle	muscl	N	O
(	(	(	(	(	N	O
s	NN	s	s	s	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
marked	VBD	marked	marked	mark	N	O
facial	JJ	facial	facial	facial	N	O
asymmetry	NN	asymmetry	asymmetry	asymmetri	N	O
,	,	,	,	,	N	O
inflammation	NN	inflammation	inflammation	inflamm	Y	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
injection	NN	injection	injection	inject	Y	O
site	NN	site	site	site	N	O
(	(	(	(	(	N	O
s	PRP	s	s	s	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
ptosis	NN	ptosis	ptosis	ptosi	Y	O
,	,	,	,	,	N	O
excessive	JJ	excessive	excessive	excess	N	O
dermatochalasis	NN	dermatochalasis	dermatochalasis	dermatochalasi	Y	O
,	,	,	,	,	N	O
deep	JJ	deep	deep	deep	N	O
dermal	NN	dermal	dermal	dermal	N	O
scarring	NN	scarring	scarring	scar	Y	O
,	,	,	,	,	N	O
thick	VBP	thick	thick	thick	N	O
sebaceous	JJ	sebaceous	sebaceous	sebac	N	O
skin	NN	skin	skin	skin	N	O
[	NNP	[	[	[	N	O
seeDosage	NN	seedosage	seedosage	seedosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
]	NN	]	]	]	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
inability	NN	inability	inability	inabl	N	O
to	TO	to	to	to	N	O
substantially	RB	substantially	substantially	substanti	N	O
lessen	VB	lessen	lessen	lessen	N	O
glabellar	JJ	glabellar	glabellar	glabellar	N	O
lines	NNS	lines	line	line	N	O
by	IN	by	by	by	N	O
physically	RB	physically	physically	physic	N	O
spreading	VBG	spreading	spreading	spread	N	O
them	PRP	them	them	them	N	O
apart	RB	apart	apart	apart	N	O
[	VB	[	[	[	N	O
seeClinical	JJ	seeclinical	seeclinical	seeclin	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.2	CD	14.2	14.2	14.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
exceed	VB	exceed	exceed	exceed	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
dosage	NN	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	B-Factor
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
ptosis	NN	ptosis	ptosis	ptosi	Y	I-AdverseReaction
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Pre	NNP	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
Neuromuscular	JJ	neuromuscular	neuromuscular	neuromuscular	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Individuals	NNS	individuals	individual	individu	N	O
with	IN	with	with	with	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	O
motor	NN	motor	motor	motor	N	O
neuropathic	JJ	neuropathic	neuropathic	neuropath	N	O
diseases	NNS	diseases	disease	diseas	N	O
,	,	,	,	,	N	O
amyotrophic	JJ	amyotrophic	amyotrophic	amyotroph	N	O
lateral	JJ	lateral	lateral	later	N	O
sclerosis	NN	sclerosis	sclerosis	sclerosi	N	O
or	CC	or	or	or	N	O
neuromuscular	JJ	neuromuscular	neuromuscular	neuromuscular	N	O
junction	NN	junction	junction	junction	N	O
disorders	NNS	disorders	disorder	disord	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
myasthenia	JJ	myasthenia	myasthenia	myasthenia	Y	O
gravis	NN	gravis	gravis	gravi	N	O
or	CC	or	or	or	N	O
Lambert	NNP	lambert	lambert	lambert	N	O
-	:	-	-	-	N	O
Eaton	NNP	eaton	eaton	eaton	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
particularly	RB	particularly	particularly	particularli	N	O
closely	RB	closely	closely	close	N	O
when	WRB	when	when	when	N	O
given	VBN	given	given	given	N	O
botulinum	NN	botulinum	botulinum	botulinum	N	O
toxin	NN	toxin	toxin	toxin	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
neuromuscular	JJ	neuromuscular	neuromuscular	neuromuscular	N	O
disorders	NNS	disorders	disorder	disord	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
effects	NNS	effects	effect	effect	N	O
including	VBG	including	including	includ	N	O
severe	JJ	severe	severe	sever	N	B-Severity
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
compromise	NN	compromise	compromise	compromis	N	I-AdverseReaction
from	IN	from	from	from	N	O
typical	JJ	typical	typical	typic	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
[	VBZ	[	[	[	N	O
seeAdverse	JJ	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Human	NNP	human	human	human	N	O
Albumin	NNP	albumin	albumin	albumin	Y	O

This	DT	this	this	thi	N	O
product	NN	product	product	product	N	O
contains	VBZ	contains	contains	contain	N	O
albumin	JJ	albumin	albumin	albumin	Y	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
derivative	NN	derivative	derivative	deriv	N	O
of	IN	of	of	of	N	O
human	JJ	human	human	human	N	O
blood	NN	blood	blood	blood	N	O
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
effective	JJ	effective	effective	effect	N	O
donor	NN	donor	donor	donor	N	O
screening	NN	screening	screening	screen	N	O
and	CC	and	and	and	N	O
product	NN	product	product	product	N	O
manufacturing	NN	manufacturing	manufacturing	manufactur	N	O
processes	VBZ	processes	process	process	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
carries	VBZ	carries	carry	carri	N	O
an	DT	an	an	an	N	O
extremely	RB	extremely	extremely	extrem	N	O
remote	JJ	remote	remote	remot	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
transmission	NN	transmission	transmission	transmiss	N	O
of	IN	of	of	of	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
diseases	NNS	diseases	disease	diseas	N	I-AdverseReaction
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
theoretical	JJ	theoretical	theoretical	theoret	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
transmission	NN	transmission	transmission	transmiss	N	O
of	IN	of	of	of	N	O
Creutzfeldt	NNP	creutzfeldt	creutzfeldt	creutzfeldt	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Jakob	NNP	jakob	jakob	jakob	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
CJD	NNP	cjd	cjd	cjd	Y	B-AdverseReaction
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
also	RB	also	also	also	N	O
considered	VBN	considered	considered	consid	N	O
extremely	RB	extremely	extremely	extrem	N	O
remote	JJ	remote	remote	remot	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
transmission	NN	transmission	transmission	transmiss	N	I-Negation
of	IN	of	of	of	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
diseases	NNS	diseases	disease	diseas	N	I-AdverseReaction
or	CC	or	or	or	N	O
CJD	NNP	cjd	cjd	cjd	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
ever	RB	ever	ever	ever	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
albumin	NN	albumin	albumin	albumin	Y	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Intradermal	NNP	intradermal	intradermal	intraderm	N	O
Immune	NNP	immune	immune	immun	N	O
Reaction	NNP	reaction	reaction	reaction	N	O

The	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
immune	JJ	immune	immune	immun	N	O
reaction	NN	reaction	reaction	reaction	N	O
when	WRB	when	when	when	N	O
injected	VBN	injected	injected	inject	N	O
intradermally	RB	intradermally	intradermally	intraderm	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

DYSPORT	NNP	dysport	dysport	dysport	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
approved	VBN	approved	approved	approv	N	O
only	RB	only	only	onli	N	O
for	IN	for	for	for	N	O
intramuscular	JJ	intramuscular	intramuscular	intramuscular	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

